EWTX — Edgewise Therapeutics, Inc.
6 mentions in the last 24 hours · 0.02% of all mentions
Why people talked about EWTX (2026-11-05)
- Edgewise Therapeutics received favorable FDA feedback for EDG-7500 and submitted a Phase 3 protocol for hypertrophic cardiomyopathy.
- The company reported Q3 2026 financial results, missing EPS and revenue estimates significantly.
- A press release was issued on November 4, 2026, detailing the financial results for the third quarter ended September 30, 2026.
| Bluesky | 4 | community |
| GDELT | 1 | news |
| SEC EDGAR 8-K | 1 | filings |